Sanofi India announced that it has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for Beyfortus. 

Beyfortus is intended to prevent Respiratory Syncytial Virus (RSV) and Lower Respiratory Tract Disease (LRTD) in newborns and infants. 

It can also be administered to children up to 24 months of age who are at risk for severe RSV disease during their second RSV season. 

RSV is a highly contagious virus that can cause serious respiratory illness in infants.

Preeti Futnani, General Manager of Sanofi Vaccines (India), said, “Prevention of RSV in India is still an unmet medical need. This makes the approval of Beyfortus a landmark moment for Sanofi in India.”

The collaboration between AstraZeneca and Sanofi to develop and commercialise Beyfortus was announced in March 2017.

Development and production are under the purview of AstraZeneca, whereas commercialisation and revenue recording are under the purview of Sanofi.

Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!